The news follows the European approval of Accofil in September 2014 [1]. 

Accofil is a biosimilar of Amgen’s Neupogen (filgrastim). The biosimilar is indicated for the same indications as neupogen, i.e. reduction in the duration of neutropenia and the incidence of febrile neutropenia, mobilization of peripheral blood progenitor cells, severe congenital, cyclic or idiopathic neutropenia and persistent neutropenia in patients with advanced HIV infection.

This latest filgrastim biosimilar brings to nine the number of filgrastim biosimilars approved for use in Europe. The first filgrastim biosimilars approved in Europe were Biograstim, Ratiograstim and Tevagrastim from CT Arzneimittel, Ratiopharm and Teva Pharmaceutical Industries, respectively [1].

Accofil is available in pre-filled syringes in dosages of 30MU/0.5 mL and 48MU/0.5 mL. The biosimilar is ‘the first of many biological products’ Accord is ‘in the process of bringing to the EU market over the coming years’.

Related articles
FDA advisers recommend approval of filgrastim biosimilar

Filgrastim biosimilar has similar safety and efficacy to Neupogen

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 27]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.